Alectinib is a kinase inhibitor used to treat anaplastic lymphoma kinase positive metastatic non small cell lung cancer. Alectinib is a second generation oral drug that selectively inhibits the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase.
- Mechanism
- Curator reviewed
Alectinib is a second generation oral drug that selectively inhibits the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase. It is specifically used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4 (echinoderm microtubule-associated protein-like 4) fusion protein that causes proliferation of NSCLC cells. Inhibition of ALK prevents phosphorylation and subsequent downstream activation of STAT3 and AKT resulting in reduced tumour cell viability. Both alectinib and its major active metabolite M4 demonstrate similar in vivo and in vitro activity against multiple mutant forms of ALK.
- Primary indication
- Alectinib is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC).Curator reviewed · 2 structured indications
- Formula / weight
- C30H34N4O2 · 482.6166 g/mol (avg)
- First approval
- Canada, 2016 · United States, 2015 · European Union, 2020
- Code names
- AF-802 · CH-5424802 · RG-7853 · RO-5424802
- Brand names
Resolves to
KDGFLJKFZUIJMX-UHFFFAOYSA-NSMILESCCC1=CC2=C(C=C1N1CCC(CC1)N1CCOCC1)C(C)(C)C1=C(C3=CC=C(C=C3N1)C#N)C2=OWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Alectinib, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account